Liraglutide

Liraglutide
Cat. No.
BT16690
Source
Synonyms
Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Purity

Greater than 97% as determined by RP-HPLC.

Usage
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

Liraglutide peptide is a single, non-glycosylated polypeptide chain containing 31 amino acids, having a molecular mass of 3751 Dalton and a Molecular formula of C172H265N43O51.

Product Specs

Introduction
Liraglutide, a long-acting GLP-1 receptor agonist, shares a 97% amino acid sequence homology with human GLP-1. A key structural difference is the substitution of arginine for lysine at position 34, and the addition of a fatty acid side chain. These modifications increase Liraglutide's resistance to degradation by the enzyme DPP-4, leading to a longer half-life compared to native GLP-1. Liraglutide's mechanism of action involves binding to GLP-1 receptors, which stimulates insulin secretion in a glucose-dependent manner. Additionally, it suppresses glucagon secretion and slows gastric emptying.
Description
Liraglutide peptide is a single-chain, non-glycosylated polypeptide comprised of 31 amino acids. It possesses a molecular mass of 3751 Daltons and a molecular formula of C172H265N43O51.
Physical Appearance
Sterile, white lyophilized powder.
Formulation
The lyophilized protein is provided at a concentration of 1 mg/ml and contains no additives.
Solubility
To reconstitute lyophilized Liraglutide, it is recommended to dissolve the powder in sterile 18 MΩ-cm H2O to a concentration of at least 100 µg/ml. This solution can then be further diluted into other aqueous solutions as needed. It's important to note that Liraglutide is also soluble in a 1% acetic acid solution.
Stability
Lyophilized Liraglutide should be stored between 2-8°C and should not be frozen. After reconstitution, the solution should be stored at 4°C and is stable for up to 7 days. For long-term storage, the reconstituted Liraglutide should be stored below -18°C. Avoid repeated freeze-thaw cycles.
Purity
The purity of this Liraglutide product is greater than 97% as determined by reverse-phase high-performance liquid chromatography (RP-HPLC).
Amino Acid Sequence

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Product Science Overview

Mechanism of Action

Liraglutide works by increasing the amount of insulin produced by the pancreas when blood sugar levels are high. It also reduces the amount of glucagon, a hormone that increases blood sugar levels, produced by the pancreas . Additionally, liraglutide slows down the emptying of the stomach, which helps to reduce appetite and food intake .

Clinical Uses
  1. Type 2 Diabetes Mellitus: Liraglutide is used as a second-line therapy for type 2 diabetes, particularly when first-line treatments like metformin are not sufficient . It helps to control blood sugar levels and has been shown to reduce the risk of cardiovascular complications associated with diabetes .

  2. Chronic Obesity: Under the brand name Saxenda, liraglutide is used for weight management in individuals with obesity. It helps to reduce appetite and increase feelings of fullness, leading to reduced food intake and weight loss .

Administration

Liraglutide is administered via subcutaneous injection, typically once daily . The dosage may vary depending on the specific condition being treated and the patient’s response to the medication.

Side Effects

Common side effects of liraglutide include nausea, vomiting, diarrhea, and constipation. Some patients may also experience headaches, dizziness, and reactions at the injection site . Serious side effects, although rare, can include pancreatitis, kidney problems, and allergic reactions .

Industrial Production

Liraglutide is synthesized using recombinant DNA technology. The production process involves the insertion of the gene encoding the GLP-1 analog into a host organism, typically Escherichia coli or Saccharomyces cerevisiae. The host organism then produces the GLP-1 analog, which is subsequently purified and formulated into the final product .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.